The surge in antibody drug conjugates investments

Big pharmaceutical companies, seeking new pathways in cancer treatment, are increasing investments in antibody drug conjugates (ADCs) developed by biotech firms. BMS recently purchased of an ADC from South Korean biotech Orum Therapeutics for $100m. The development of ADCs involves combining chemotherapies with monoclonal antibodies to specifically target cancer cells, reducing side-effects. ADCs are valued at $9.7bn in 2023 and are expected to double to $19.8bn in five years.